Physician profile
Ryan A Valicek
NPI 1386817039
$22,919.02
in general payments reported to CMS, 2019-2025
39 companies · $4,044 in 2025
The $4,044 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,723 · 2020: $1,994 · 2021: $2,799 · 2022: $2,346 · 2023: $3,101 · 2024: $4,912 · 2025: $4,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,377.53 |
| Consulting Fee | $1,680.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,987.93 | 2019-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $3,483.73 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,463.92 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,997.37 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,716.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,452.88 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $1,327.60 | 2019-2025 | Orencia, Sotyktu |
| Lilly USA, LLC | $951.19 | 2019-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $713.55 | 2019-2025 | |
| Genzyme Corporation | $655.44 | 2019-2025 | |
| Glaxosmithkline, LLC. | $654.35 | 2019-2025 | Benlysta, Nucala |
| Fresenius Kabi USA, LLC | $398.36 | 2023-2025 | Idacio |
| Genentech USA, INC. | $380.93 | 2019-2025 | Gazyva |
| Horizon Therapeutics Plc | $331.58 | 2019-2023 | Krystexxa |
| Celgene Corporation | $289.33 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $275.07 | 2021-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.72 | 2019-2024 | Ofev, Cyltezo |
| Mallinckrodt Enterprises LLC | $176.21 | 2019 | |
| Aurinia Pharma U.S., INC. | $160.67 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $158.41 | 2020-2025 | Acthar |
| Organon LLC | $131.00 | 2023-2025 | Renflexis, Hadlima |
| Radius Health, INC. | $125.99 | 2019-2023 | Tymlos |
| Invivyd INC | $119.90 | 2025 | Pemgarda |
| Sobi, INC | $118.66 | 2019-2025 | |
| Octapharma USA, INC. | $102.09 | 2021-2023 | Panzyga |
| Antares Pharma, INC. | $77.51 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $76.46 | 2019 | |
| Ani Pharmaceuticals, INC. | $50.02 | 2022 | |
| Gilead Sciences, INC. | $48.10 | 2019-2020 | |
| Zyla Life Sciences, INC. | $41.90 | 2019 | |
| Bioventus LLC | $40.07 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $39.75 | 2021-2024 | Crysvita |
| Grt US Holding, INC. | $28.56 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $27.54 | 2023 | Opsumit |
| Medtronic, INC. | $26.22 | 2024 | Venaseal |
| Kyowa Kirin, INC. | $25.85 | 2024 | Crysvita |
| Mylan Institutional INC. | $20.62 | 2023 | |
| Medexus Pharma, INC. | $13.07 | 2019 | |
| Hikma Pharmaceuticals USA | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Valicek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.